Compare COO & LII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COO | LII |
|---|---|---|
| Founded | 1980 | 1895 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 17.7B |
| IPO Year | N/A | 1999 |
| Metric | COO | LII |
|---|---|---|
| Price | $80.89 | $493.87 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 11 | 12 |
| Target Price | $88.55 | ★ $603.36 |
| AVG Volume (30 Days) | ★ 3.8M | 472.7K |
| Earning Date | 12-04-2025 | 01-28-2026 |
| Dividend Yield | N/A | ★ 1.03% |
| EPS Growth | N/A | ★ 12.46 |
| EPS | 1.87 | ★ 23.67 |
| Revenue | $4,092,400,000.00 | ★ $5,345,300,000.00 |
| Revenue This Year | $6.66 | N/A |
| Revenue Next Year | $5.54 | $7.34 |
| P/E Ratio | $43.89 | ★ $21.37 |
| Revenue Growth | ★ 5.06 | 3.77 |
| 52 Week Low | $61.78 | $443.19 |
| 52 Week High | $100.24 | $689.44 |
| Indicator | COO | LII |
|---|---|---|
| Relative Strength Index (RSI) | 63.53 | 48.50 |
| Support Level | $77.64 | $497.54 |
| Resistance Level | $82.92 | $525.00 |
| Average True Range (ATR) | 2.37 | 13.20 |
| MACD | 0.27 | 1.63 |
| Stochastic Oscillator | 39.37 | 25.37 |
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
Lennox International manufactures and distributes heating, ventilating, air conditioning, and refrigeration products to replacement (75% of sales) and new construction (25% of sales) markets. In fiscal 2024, residential HVAC was 67% of sales and commercial HVAC and Heatcraft refrigeration was 33% of sales. The company goes to market with multiple brands, but Lennox is the company's flagship HVAC brand. The Texas-based company is focused on North America after the sale of its European HVAC and refrigeration businesses in late 2023.